A biotech startup let an agent choose a gene therapy and successfully inject the treatment, offering a startling glimpse of the future of research labs.
In breathless press releases and posts, the company has touted its models’ ability to deliver scientific breakthroughs. But its IPO filing taps the brakes on just how fast its AI will lead to big discoveries.
The new open-source model speaks the language of DNA and can help researchers understand the effects of any changes on gene activity and health.
It’s the latest in a growing wave of bets that AI companies are making on brain data.
The death of a lab worker in Russia has authorities looking at whether plague played a role. Even if it did, though, the odds of it spreading are very low.
The US resurgence of measles is forcing hospitals and health systems to adopt new protocols and procedures to deal with a disease they thought was in the past.
The device made by Flow Neuroscience is approved by the FDA and could help people get off antidepressants—but it costs $2,200.
With the risk of infection rising, parents and young adults are facing agonizing choices about being out in public as school starts back up.
Gene-edited pig kidneys could offer a lifeline to patients stuck waiting for a human donor.
The fatalities come amid declining vaccination rates and calls from President Donald Trump to split up the MMR vaccine.